Drugs / LX3305
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01417052 | Sep 2011 → Jun 2012 | rheumatoid arthritis | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00847886 | Feb → Mar 2009 | rheumatoid arthritis | Lexicon Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00903383 | Jul 2009 → Sep 2010 | rheumatoid arthritis | Lexicon Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX3305 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00847886 ↗ |
| Known as | LX 2931 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1852164 ↗ |
| Modality | Small molecule | — CHEMBL1852164 ↗ |
| Route | Oral | “Daily oral intake of LX3305 for 14 days.” NCT00847886 ↗ |